Gemcitabin and Abraxane for Ovarian Cancer – pro
An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months.
Gemcitabine and Abraxane is not a well studies regimen for recurrent ovarian cancer, and ti was not icnluded in the recent review by Foley at al. I did not, in fact, find studies supporting it in this setting. While reasonable, and each one of this drug singly is NCCN supported, confirmation from randomized studies is needed before a treatment can be routinely adopted.
Micha JP, ET AL, Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. : Gynecol Oncol. 2006 Feb;100(2):437-8. Epub 2005 Oct
Olivia W. Foley, BSJ. Alejandro Rauh-Hain, MDMarcela G. Del Carmen, MD, MPH, Recurrent Epithelial Ovarian Cancer: An Update on Treatment. Oncology. 27, April 16, 2013 Volume: 27
NCCN, Ovarian 2017